The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis

Weißbrich, Benedikt

doi:10.1002/(sici)1096-9071(199802)54:2<145::aid-jmv13>3.0.co;2-i

Cited by 19 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the presence of IgM negativity resulting from inappropriate timing of blood sampling or the loss of EBNA antibodies owing to a suppressed immune system can obscure the identifi cation of primary infections or can lead to misdiagnosis. In such cases, it is suggested that the study of IgG avidity is critical to interpreting serological results correctly (9)(10)(11)(12). In general, the kinetics of affi nity maturation occurs in a couple of weeks; however, in some cases this maturation process may arise within three months after the onset of symptoms.…”

Section: Discussionsupporting

confidence: 47%

“…Moreover, the determination of specifi c IgG antibody avidity is performed thorough various techniques including agglutination, radioimmunoassay, complement fi xation, ELISA, immunofl uorescence, electroblotting, immunoblot (16). However, some studies suggest that immunoblot is easier to interpret, as compared to ELISA and is the preferred method for measuring avidity (12,21). Immunofl uorescence assay (IFA) is used widely for detecting EBV-specifi c antibodies because of its high sensitivity and specifi city.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of serological profiles and avidity of specific antibodies in the sera of patients with potential Epstein-Barr virus (EBV) infection

Akpolat¹,

Gedik²,

Nergiz³

et al. 2013

BLL

View full text Add to dashboard Cite

Abstract:Background: Epstein-Barr Virus, frequently referred to as EBV, is a member of the herpesvirus family and one of the most common human viruses. The virus occurs worldwide, and most people become infected with EBV sometime during their lives. Objectives: The purpose of this study was to investigate the serological profi les of specifi c antibodies among the sera of suspected EBV infection patients along with VCA-IgG avidity. Methods: A total of 522 patient's sera were sent to The Clinical Microbiology Laboratory for EBV specifi c antibody detection and were studied by IFA method during a two year period. The serum samples were tested for EBV specifi c VCA IgG, VCA IgM, EA, EBNA antibodies and VCA IgG aviditity. Results: Among 33 patients those who had low avidity for VCA IgG, 27 (81.8 %) of them had a serologic profi le as follows; positive VCA IgG, negative VCA IgM, negative EA and negative EBNA. Conclusion: While this profi le is considered as a primary infection, the frequency of the coexistence of VCA IgG low avidity with this profi le is interepreted that avidity may lead to detect primary infection (Tab. 2, Ref. 25 Abbreviations: IFA -indirect fl uorescent antibody, EBV -Epstein-Barr virus, EA -early antigen,VCA -viral capsid antigen, EBNA -epstein-barr nuclear antigen.Epstein-Barr virus, commonly referred to as EBV, is a human specifi c member of the herpesvirus family and is a B-cell lymphotropic virus. An EBV infection occurs by close contact with EBV presented in oral secretions. The virus initially wells in the oropharyngeal epithelial cells and causes persistent infections. Seroepidemiologic studies indicate that EBV infections are common in all communities and occur worldwide, and most people become infected with EBV sometime during their lives. In Europe including Turkey, as many as 70-80 % of adolescents and 80-90 % of adults are reported to be seropositive for EBV (1).The course of EBV infection can vary with regard to the age and health status of the person. In young children host-virus infection can take place with no apparent symptoms. By contrast, in 30-50 % of the adult patients EBV infection can cause diffuse lymphadenopathy, hepatomegaly, splenomegaly, and tonsillitis. In some cases exanthematous reactions triggered by EBV can be mistaken with an eruption of rubella (2). Moreover, EBV infection is shown to be associated with lymphoproliferative disorders in patients who are suffering from immunodefi ciency, Burkitt lymphoma, and nasopharyngeal carcinoma (3,4). Infectious mononucleosis is also caused by infection of B cells by EBV and is generally diagnosed by serological methods. EBV serology is utilized to help distinguish EBV reactivation infections from primary EBV infections and to demonstrate acute EBV infections. During this process, it is critically important to perform the tests at the same time for the presence of EBV-VCA IgM, EBV-VCAIgG, anti-EBV-EA, anti EBV-EBNA and VCA IgG avidity (2).The spectrum of antibody assays comprises unspecifi c tests, such as the long-known te...

show abstract

Section: Discussionsupporting

confidence: 47%

Section: Discussionmentioning

confidence: 99%

Determination of serological profiles and avidity of specific antibodies in the sera of patients with potential Epstein-Barr virus (EBV) infection

Akpolat¹,

Gedik²,

Nergiz³

et al. 2013

BLL

View full text Add to dashboard Cite

show abstract

“…In addition to a mix of antigens, it is possible to use the whole or specific VCA (p23 or p18), IEA (ZEBRA), EA (p138 or p54) or EBNA (p72). Avidity varies depending on the kinetics of the various antibodies [63,66] , e.g. in VCA IgG, it has been reported that avidity is low in the samples collected during the first 12 wk after symptom onset, thus indicating recent infection [67] .…”

Section: Igg Aviditymentioning

confidence: 99%

Serological diagnosis of Epstein-Barr virus infection: Problems and solutions

Paschale

Clerici²

2012

WJV

255

272

View full text Add to dashboard Cite

Serological tests for antibodies specific for Epstein-Barr virus (EBV) antigens are frequently used to define infection status and for the differential diagnosis of other pathogens responsible for mononucleosis syndrome. Using only three parameters [viral capsid antigen (VCA) IgG, VCA IgM and EBV nuclear antigen (EBNA)-1 IgG],it is normally possible to distinguish acute from past infection: the presence of VCA IgM and VCA IgG without EBNA-1 IgG indicates acute infection, whereas the presence of VCA IgG and EBNA-1 IgG without VCA IgM is typical of past infection. However, serological findings may sometimes be difficult to interpret as VCA IgG can be present without VCA IgM or EBNA-1 IgG in cases of acute or past infection, or all the three parameters may be detected simultaneously in the case of recent infection or during the course of reactivation. A profile of isolated EBNA-1 IgG may also create some doubts. In order to interpret these patterns correctly, it is necessary to determine IgG avidity, identify anti-EBV IgG and IgM antibodies by immunoblotting, and look for heterophile antibodies, anti-EA (D) antibodies or viral genome using molecular biology methods. These tests make it possible to define the status of the infection and solve any problems that may arise in routine laboratory practice.

show abstract

“…Low concentrations of urea (e.g. 4.7M), however, have been used for showing low avidity IgG anti-EBV (Weissbrich 1998).…”

Section: Discussionmentioning

confidence: 99%

Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection

Pereira¹,

Paula²,

Cubel³

et al. 2001

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis

Cited by 19 publications

References 34 publications

Determination of serological profiles and avidity of specific antibodies in the sera of patients with potential Epstein-Barr virus (EBV) infection

Determination of serological profiles and avidity of specific antibodies in the sera of patients with potential Epstein-Barr virus (EBV) infection

Serological diagnosis of Epstein-Barr virus infection: Problems and solutions

Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection

Contact Info

Product

Resources

About